CompletedNot Applicable

755nm Alex Laser for Treatment of Pigmented and Vascular Lesions and Scars

United States43 participantsStarted 2011-10

Plain-language summary

Evaluation of the safety and efficacy of the 755nm Alex laser for the treatment of benign pigmented and vascular lesions and scars

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Healthy male or female subjects between 18 and 85 years of age.
✓. Subjects with Fitzpatrick skin types I to VI.
✓. Subjects who have unwanted pigmented lesions, vascular lesions, striae and/or hypertrophic or atrophic scars
✓. Subject who are willing to consent to participate in the study.

✕. Subject who will not be photographed or who will not cooperate with the post treatment care and follow up schedule
✕. Hypersensitive to light exposure.
✕. Active localized or systemic infections.
✕. Taking medication for which sunlight is a contraindication.
✕. History of squamous cell carcinoma or melanoma.
✕. History of keloid scarring.
✕. Use of oral isotretinoin (Accutane®) within 12 months of initial treatment or during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment.
✕. Prior treatment with laser or other devices in treatment area within 3 months

Clearance Based on Photographic Scale

Timeframe: 1 months post last treatment

Clearance Based on Photographic Scale

Timeframe: 3 months post last treatment

NCT IDNCT01745627

SponsorCynosure, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-12

Results submitted2020-10-21